Abstract
Data on 68 146 hematopoietic stem cell transplants (HSCTs) (53% autologous and 47% allogeneic) gathered by 1566 teams from 77 countries and reported through their regional transplant organizations were analyzed by main indication, donor type and stem cell source for the year 2012. With transplant rates ranging from 0.1 to 1001 per 10 million inhabitants, more HSCTs were registered from unrelated 16 433 donors than related 15 493 donors. Grafts were collected from peripheral blood (66%), bone marrow (24%; mainly non-malignant disorders) and cord blood (10%). Compared with 2006, an increase of 46% total (57% allogeneic and 38% autologous) was observed. Growth was due to an increase in reporting teams (18%) and median transplant activity/team (from 38 to 48 HSCTs/team). An increase of 167% was noted in mismatched/haploidentical family HSCT. A Strengths, Weaknesses, Opportunities, Threats (SWOT) analysis revealed the global perspective of WBMT to be its major strength and identified potential to be the key professional body for patients and authorities. The limited data collection remains its major weakness and threat. In conclusion, global HSCT grows over the years without plateauing (allogeneic>autologous) and at different rates in the four World Health Organization regions. Major increases were observed in allogeneic, haploidentical HSCT and, to a lesser extent, in cord blood transplantation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
World Health Organization. WHO guiding principles on human cell, tissue and organ transplantation. Transplantation 2010; 90: 229–233.
White SL, Hirth R, Mahíllo B, Domínguez-Gil B, Delmonico FL, Noel L et al. The global diffusion of organ transplantation: trends, drivers and policy implications. Bull World Health Organ 2014; 92: 826–835.
Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A et al. Worldwide Network of Blood and Marrow Transplantation. Hematopoietic stem cell transplantation: a global perspective. JAMA 2010; 303: 1617–1624.
Gratwohl A, Baldomero H, Gratwohl M, Aljurf M, Bouzas LF, Horowitz M et al. Worldwide Network of Blood and Marrow Transplantation (WBMT). Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study. Haematologica 2013; 98: 1282–1290.
Gratwohl A, Pasquini MC, Aljurf M, Yoshiko A, Helen B, Lydia F et al. For the Worldwide Network of Blood and Marrow Transplantation WBMT. One million haemopoietic stem- cell transplants: a retrospective observational study. Lancet Haematol 2015; 2: e91–100.
Copelan EA . Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354: 1813–1826.
Sureda A, Bader P, Cesaro S, Dreger P, Duarte RF, Dufour C et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant 2015; 50: 1037–1056.
Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P et al. European Society for Blood and Marrow Transplantation (EBMT). Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. Bone Marrow Transplant 2015; 50: 476–482.
Hequet O . Hematopoietic stem and progenitor cell harvesting: technical advances and clinical utility. J Blood Med 2015; 6: 55–67.
Kurata M, Yanagisawa A, Atsuta Y, Sakamaki H, Kato K, Ichinohe T et al. Hematopoietic cell transplantation in Japan: nationwide survey 2013. Rinsho Ketsueki 2014; 55: 2381–2399.
Aljurf M, Rizzo JD, Mohty M, Hussain F, Madrigal A, Pasquini MC et al. Challenges and opportunities for HSCT outcome registries: perspective from international HSCT registries experts. Bone Marrow Transplant 2014; 49: 1016–1021.
Casebeer A . Application of SWOT analysis. Br J Hosp Med 1993; 49: 430–431.
Yamazaki H, Slingsby BT, Takahashi M, Hayashi Y, Sugimori H, Nakayama T . Characteristics of qualitative studies in influential journals of general medicine: a critical review. Biosci Trends 2009; 3: 202–209.
Reisner Y, Aversa F, Martelli MF . Haploidentical hematopoietic stem cell transplantation: state of art. Bone Marrow Transplant 2015; 50 (Suppl 2): S1–S5.
Ballen KK, Gluckman E, Broxmeyer HE . Umbilical cord blood transplantation: the first 25 years and beyond. Blood 2013; 122: 491–498.
Petrini C . Umbilical cord blood banking: from personal donation to international public registries to global bioeconomy. J Blood Med 2014; 5: 87–97.
Kekre N, Antin JH . Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist. Blood 2014; 124: 334–343; Erratum in: Blood 2015; 125: 1048.
Halter JP, van Walraven SM, Worel N, Bengtsson M, Hägglund H, Nicoloso de Faveri G et al. Allogeneic hematopoietic stem cell donation-standardized assessment of donor outcome data: a consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT). Bone Marrow Transplant 2013; 48: 220–225.
Kodera Y, Yamamoto K, Harada M, Morishima Y, Dohy H, Asano S et al. Japan Society for Hematopoietic Cell Transplantation. PBSC collection from family donors in Japan: a prospective survey. Bone Marrow Transplant 2014; 49: 195–200.
Vogl DT, Stadtmauer EA . High-dose chemotherapy and autologous hematopoietic stem cell transplantation for metastatic breast cancer: a therapy whose time has passed. Bone Marrow Transplant 2006; 37: 985–987.
Martin I, Ireland H, Baldomero H, Passweg J . The survey on cellular and engineered tissue therapies in Europe in 2012. Tissue Eng Part A 2015; 21: 1–13.
Acknowledgements
The cooperation of all participating teams, countries and organizations with their staff is greatly appreciated. Specifically the following: ABMTRR, APBMT, Aichi Medical School, CBMTG, CIBMTR, Medical College of Wisconsin, EBMT: Co-ordination offices in Barcelona, Paris and London and the Austrian Registry (ASCTR), the Czech BMT Registry, the French Registry (SFGM), the German Registry (DRST), the Italian Registry (GITMO), the Dutch Registry (HOVON), the Spanish BMT Registry (GETH), the Swiss Registry (SBST), the Turkish BMT Registry and the British Registry (BSBMT), EMBMT, SBTMO, LABMT, AFBMT, WMDA and Eurocord. Funding was provided by the participating organizations. The WBMT activity survey office is funded by the EBMT and the University of Basel. Funding was solely to support the study; no individual payment was made to any of the persons involved in the study.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on Bone Marrow Transplantation website
Rights and permissions
About this article
Cite this article
Niederwieser, D., Baldomero, H., Szer, J. et al. Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transplant 51, 778–785 (2016). https://doi.org/10.1038/bmt.2016.18
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2016.18
This article is cited by
-
Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT
Bone Marrow Transplantation (2024)
-
Effects of pulmonary rehabilitation in hematopoietic stem cell transplantation recipients: a randomized controlled study
Supportive Care in Cancer (2024)
-
The effect of conditioning regimen and prescribed medications on hyposalivation in haematopoietic cell transplantation (HCT) patients: an 18-month prospective longitudinal study
Clinical Oral Investigations (2023)
-
Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey
Bone Marrow Transplantation (2023)
-
Coexistence of HLA and KIR ligand mismatches as a risk factor for viral infection early after cord blood transplantation
Bone Marrow Transplantation (2022)